Oxford, UK – 17 July 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a standing-room-only workshop at the European Society of Human Genetics (ESHG) 2012 conference in Nürnberg, Germany (June 23-26). The 200 attendees who managed to secure a place at the event enjoyed talks from international experts discussing the use of arrays and next generation sequencing (NGS) to identify causative mutations in cancer and rare disease samples. Due to the popularity of the workshop, OGT has now made the recording of the sequencing presentation from the event freely available to view by visiting the OGT website.
Among those speaking were Dr Dan Swan, a Senior NGS Computational Biologist at OGT, and Professor Jacqueline Schoumans, head of the Cancer Cytogenetic Unit in Lausanne University Hospital, Switzerland. Dr Swan presented data produced during recent customer collaborations utilising OGT’s Genefficiency™ Targeted Sequencing Service, which is designed to facilitate the rapid interpretation of vast NGS datasets. Results are presented in an intuitive, filtered report, with links to relevant external databases that provide in-depth information on each variant. The workshop also provided the first taste of OGT’s upcoming Genefficiency™ RNA-Seq Service, which is currently open to early access customers wishing to enjoy the same level of meaningful data analysis provided by OGT’s Targeted Sequencing Service. Contact OGT for more information.
At the same workshop, Professor Schoumans discussed her team’s recently published1 study comparing the performance of several array platforms. The results led to the group’s collaboration with OGT, and the subsequent development of a new, optimised array for investigating genomic variation in haematological and solid cancers. By combining OGT’s proprietary copy number and single nucleotide polymorphism (SNP) probe technology, the array provides highly sensitive detection of a wide range of variants, and will soon be available via OGT’s CytoSure™ range of cytogenetic analysis products. An interview with Professor Schoumans regarding her research and choice of array platform, conducted at ESHG by Justin Petrone for GenomeWeb, is freely available to download from OGT’s website.
To view the sequencing presentation or to read the interview with Professor Schoumans, please visit www.ogt.co.uk/eshg2012.
1. Simons, A. et al (2012) Genome-wide arrays in routine diagnosis of hematological malignancies. Human Mutation, 33, 941-948
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com
W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.